Once again showing the innovative character and the agility to develop precision PCR assays for the control of epidemic outbreaks, GPS ™ has already designed a kit of qPCR reagents for the rapid genetic detection of the Monkeypox. 

Friday, May 20, 2022. The Spanish company with the Genetic PCR Solutions™ (GPS™) brand, has already designed a kit of qPCR reagents for the rapid genetic detection of the Monkeypox virus responsible of the monkeypox disease, which has been detected in Spain and other countries such as the United Kingdom, Portugal, Italy, Sweden, France, Belgium, Germany, Canada, and USA. The GPS™ technical team has completed the design and development work on this kit, which began as a priority when it received confirmation of the news from the Instituto de Salud Carlos III. Although reference laboratories have techniques for detecting this virus, the Center for Disease Control (CDC), Atlanta, USA, has indicated that there is currently no commercial qPCR kit available to facilitate surveillance if required. GPS™ laboratories are validating its development following strict recommendations of international standards and, later, it will be tested in hospitals with real and reference samples. The company from Alicante has planned that the kit may be available at the end of next week, which will allow any laboratory to carry out specific tests to detect the Monkeypox virus. At the present time GPS™ has already received the interest of several hospital centres for the use of this qPCR currently under validation. With this new diagnostic kit GPS™, once again, shows the innovative character and the agility to develop precision PCR assays for the control of epidemic outbreaks that threaten global health. In 2016, generated the first genetic kit for the detection of the Zika virus and in January 2020 it was one of the first companies worldwide to develop efficiently the kit for the detection of SARS-CoV-2, which causes CoVID-19.